3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Squamous Intraepithelial Lesions
1
Skin Neoplasms
1
Precancerous Conditions
1
Papillomavirus Infections
1
Papilloma
1
Lung Neoplasms
1
Laryngeal papillomatosis
1
Keratosis, Actinic
1
Hyperthermia
1
HIV Infections
1
Cicatrix
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Etoposide
4
Cyclophosphamide
4
Vincristine
3
Specimen Handling
3
Prednisone
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
Biopsy
3
fludarabine phosphate
2
cabozantinib
2
Whole-Body Irradiation
2
Watchful Waiting
2
Rituximab
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Light Coagulation
2
Imiquimod
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Gene Expression Profiling
2
Fluorouracil
2
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
prednylidene
1
pembrolizumab
1
fludarabine
1
emvododstat
1
efineptakin alfa
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
HIV Infections
×
Laser Therapy
×
Clear all
NCT02135419
2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3
Completed
4,446 enrolled
13 charts